{
    "title": "105_hr2009",
    "content": "The text chunk \"SECTION 1. SHORT TITLE; FINDINGS.\" is a condensed summary of the section title and findings. The \"Amyotrophic Lateral Sclerosis (ALS) Research, Treatment, and Assistance Act of 1997\" recognizes ALS as a progressive neuromuscular disease with no known cure, affecting around 30,000 individuals in the US annually. The \"Amyotrophic Lateral Sclerosis (ALS) Research, Treatment, and Assistance Act of 1997\" aims to assist individuals with ALS by providing medicare coverage for outpatient drugs and therapies, waiving the waiting period for medicare eligibility, and increasing federal funding for ALS research. There is no known cure for ALS, but aggressive treatment of symptoms can extend patients' lives. Recent advances in research show promising leads related to shared disease processes in neurodegenerative diseases. The \"Amyotrophic Lateral Sclerosis (ALS) Research, Treatment, and Assistance Act of 1997\" aims to provide medicare coverage for individuals disabled with ALS by waiving the 24-month waiting period for eligibility. The \"Amyotrophic Lateral Sclerosis (ALS) Research, Treatment, and Assistance Act of 1997\" amends the Social Security Act to provide special rules for individuals with ALS, waiving the waiting period for benefits eligibility. The Social Security Act is amended to provide special rules for individuals with ALS, waiving the waiting period for benefits eligibility. The amendments apply to benefits for months beginning after the enactment of the Act. The Social Security Act is amended to provide Medicare coverage for drugs treating ALS. Additionally, there will be increased federal funds for ALS research. Authorized $25,000,000 for ALS research through NIH for fiscal year 1998, with additional funding for 1999-2002."
}